ABSTRACT
Biological agents targeting inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) have emerged in recent years as effective medications for a variety of inflammatory arthropathies. Although the relationship between the use of anti-TNF drugs and an increase in the rate of infections is well established, the role of these drugs in the development of different types of cancer is unclear. Randomized clinical trials and national registries have not demonstrated a significant increase in the risk of cancer in patients treated with anti-TNF drugs, but numerous cases of the appearance of malignant tumors in patients receiving these drugs have been reported. We describe the case of a 73-year-old man, ex-smoker, who developed a lung cancer during treatment with infliximab further complicated by perforation of a metastasis in the sigmoid colon, which is a very infrequent event in the course of this malignancy. A few similar cases previously reported in the literature are reviewed.
Subject(s)
Adenocarcinoma/secondary , Antibodies, Monoclonal/adverse effects , Colonic Neoplasms/complications , Colonic Neoplasms/secondary , Intestinal Diseases/etiology , Intestinal Perforation/etiology , Lung Neoplasms/secondary , Spondylitis, Ankylosing/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adenocarcinoma/chemically induced , Adenocarcinoma of Lung , Aged , Antibodies, Monoclonal/therapeutic use , Humans , Infliximab , Lung Neoplasms/chemically induced , MaleABSTRACT
No disponible
